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MicroRNAs (miRs) have emerged as important gene silencers affecting many target
mRNAs. Here, we report the identiﬁcation of 244 miRs that target the 3′-untranslated
regions of different cholinesterase transcripts: 116 for butyrylcholinesterase (BChE), 47 for
the synaptic acetylcholinesterase (AChE-S) splice variant, and 81 for the normally rare splice
variant AChE-R. Of these, 11 and 6 miRs target both AChE-S and AChE-R, and AChE-R and
BChE transcripts, respectively. BChE and AChE-S showed no overlapping miRs, attesting
to their distinct modes of miR regulation. Generally, miRs can suppress a number of tar-
gets; thereby controlling an entire battery of functions. To evaluate the importance of the
cholinesterase-targeted miRs in other speciﬁc biological processes we searched for their
other experimentally validated target transcripts and analyzed the gene ontology enriched
biological processes these transcripts are involved in. Interestingly, a number of the result-
ing categories are also related to cholinesterases. They include, for BChE, response to
glucocorticoid stimulus, and for AChE, response to wounding and two child terms of neu-
ron development: regulation of axonogenesis and regulation of dendrite morphogenesis.
Importantly, all of the AChE-targetingmiRs found to be related to these selected processes
were directed against the normally rare AChE-R splice variant, with three of them, including
the neurogenesis regulator miR-132, also directed against AChE-S. Our ﬁndings point at
the AChE-R splice variant as particularly susceptible to miR regulation, highlight those bio-
logical functions of cholinesterases that are likely to be subject to miR post-transcriptional
control, demonstrate the selectivity of miRs in regulating speciﬁc biological processes, and
open new venues for targeted interference with these speciﬁc processes.
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INTRODUCTION
MicroRNAs (miRs) are small RNA molecules which target many
mRNA transcripts, leading to their post-transcriptional silenc-
ing (Bartel, 2009). Many mRNAs can be silenced by multiple
miRs and miRs often target more than one mRNA participat-
ing in a particular biological function (Bartel, 2009). Together,
this suggests that the miR networks affecting speciﬁc mRNA tran-
scripts may provide useful information on the biological roles in
which these transcripts are involved. Cholinesterases are involved
in many biological functions (Massoulie, 2002). However, miR-
132 is the only miR so far that has been experimentally validated
as targeting AChE, with consequences on inﬂammatory responses
(Shaked et al., 2009). To delineate additional miRs which might
regulate cholinesterase functions, we explored the 3′-untranslated
regions (3′-UTR) of human cholinesterase transcripts (acetyl- and
butyrylcholinesterase, AChE, BChE; Soreq and Seidman, 2001).
Given that several of the proteins involved in a speciﬁc function
are often repressed by the samemiR (Girardot et al., 2010), changes
in a particularmiRmight down-regulate the entire process.Hence,
we surmised that those functions that are shared by cholinesterases
and the other targets of the cholinesterase-complementary miRs
would be more susceptible for being affected by miR control
than other processes. That concept is schematically presented as a
workﬂow in Figure 1.
MATERIALS AND METHODS
MicroRNA candidates were identiﬁed on each of the 3′-UTR
sequences of AChE and BChE, which are 235, 1030, and 478
nucleotides long for BChE, the major “synaptic” AChE-S variant
and the stress-inducible AChE-R variant, respectively (Figure 2A).
We used the PicTar1,miRanda2,miRbase3, andmicroCosm4 algo-
rithms to identify these transcript-speciﬁc miRs. All predictions
ensured a threshold P-value< 0.05, and analysis speciﬁcations
allowed both evolutionarily conserved and non-conserved miRs,
which enabled us to include primate-targeting miRs as well.
Validation of miR-target interactions generally involved a
3′UTR luciferase assay. In some cases, it was complemented by
protein blots, real-time RT-qPCR, microarrays, transgenic tech-





Frontiers in Molecular Neuroscience www.frontiersin.org October 2011 | Volume 4 | Article 28 | 1
Hanin and Soreq Cholinesterase-targeting microRNAs
FIGURE 1 |The study’s flow chart. MicroRNAs complementary to the
3′-UTR domains of AChE and BChE transcripts were identiﬁed using several
algorithms and other validated targets for those miRs were searched for
and analyzed for common biological processes in which both these miR
targets and cholinesterases are involved.
the Shaked et al. (2009) report for several of the latter technologies
used to explore themiR-132 targetAChE, and (Hansen et al., 2010)
for the “classical” 3′-UTR and transgenic approaches, in exploring
p250GAP which is also a miR-132 target.
To search for gene ontology (GO) categories which are also rel-
evant for the other mRNA targets of cholinesterase-related miRs,
we used the DAVID functional annotation clustering tool5. For
each of the miRs identiﬁed as targeting one of the cholinesterases
we searched for other experimentally validated targets; and we
then used the lists of the other validated targets as gene lists for
the DAVID search. Each list was normalized to the entire human
genome, which served as a background.
RESULTS
We identiﬁed 116, 81, and 47 miRs (24, 8, and 20 miRs/100
nucleotides) that are complementary to the 3′-UTR domains of
the BChE,AChE-R, andAChE-S transcripts, respectively. Of these,
6 miRs target both BChE and AChE-R whereas 11 miRs are com-
mon to both AChE-R and AChE-S, but BChE and AChE-S do
not share any miR (Figure 2B). Positions of the identiﬁed miRs
are presented in Figure 2C, with miR-132 targeting a similar seed
domain localized at the very 3′-end of the 3′-UTR in both the
AChE-S and AChE-R transcripts. Of the cholinesterase-targeting
miRs, seven had multiple binding sites to the target AChE-S, nine
to AChE-R, and seven to the BChE transcript, suggesting that they
have a higher prospect for being functional (John et al., 2004).
5http://david.abcc.ncifcrf.gov/
FIGURE 2 | Cholinesterase-targeted miRs show distinct 3′UTR
distributions and partial overlaps. (A)The length of the studied 3′UTR
domains. (B) Each 3′-UTR is targeted by many different miRs, part of which
shared by BChE/AChE-R and AChE-R/AChE-S. (C) Gene and transcript
compositions (exons shown as boxes, introns – as lines) and miR
distribution patterns on the 3′-UTR domain (not to scale). Overlaps are color
coded. MiR (diamonds) localizations are marked. Black stars show miR-132
position.
Compatiblewith the different conceptual principles onwhich each
of the algorithms employed is based,only 8.6,17,and13.7%(7/81),
(8/47), (16/116) of themiRs identiﬁed as targetingAChE-R,AChE-
S, and BChE, respectively, were predicted by more than one of the
algorithms. For AChE-R, these are hsa-miR-28-5p, -423-3p, -484,
-483-5p, -663, -582-3p, -380∗. For AChE-S, hsa-miR-194, -939,
-658, -608,-615-5p, -423-5p -920, and let-7f-2∗ and for BChE,
hsa-miR-203, -218, -221, -222, -181a, -181b, -181c, -181d, -494,
-200b, -200c, -576-3p, -16-2∗, -625, -195∗, -889.
These cholinesterase-targeting miRs and their other validated
non-cholinesterase targets are listed in Tables 1–3 with the cor-
responding functions attributed to these other targets. The rel-
evant citations appear in Tables A1–A4 in Appendix. Of note,
numerous cholinesterase-targeting miRs have no experimentally
validated targets at this time, yet others have more than one vali-
dated target and associate with more than one biological function.
Examples include miR-124 which targets both the AChE-S and
IQGAP1-(Furuta et al., 2010), a GTPase activating protein which
promotes neurite outgrowth (Table 1). Additionally miR-152 and
miR-148a, which target AChE-R, also target the calmodulin reg-
ulating kinase CaMKIIα (Liu et al., 2010; Table 2). Lastly, the
BChE-targeting cluster of miRs-222 and -221 also target the
neuronal early immediate protein c-fos (Ichimura et al., 2010;
Table 3).
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Table 1 | Additional targets of AChE-S targeting microRNAs.
miR ID Validated targets
hsa-miR-491-5p Bcl-X(L; cell death)
hsa-miR-605 Mdm2 (ubiquitination)
hsa-miR-608 CD44 (cell–cell/cell–matrix interaction) CDC42 (cell division)
hsa-miR-124 Glucocorticoid receptor LAMC1 (laminin γ1) IQGAP1(neurite outgrowth; Furuta
et al., 2010)
NeuroD1 (neurogenic differentiation 1) BAF53a (chromatin remodeling) C14orf24 (chromosome 14 ORF 24)
Mtpn (myotrophin) PTBP1 (splicing) CDK6 (cyclin-dependent kinase 6)
Mapk14 (mitogen activated protein kinase 14) PTBP2 (splicing) SOX9 (glial cell speciﬁcation)
CDK2 (cyclin-dependent kinase 2) C/EBPα (transcription) Lhx2 (transcription)
MCP1 (monocyte chemoattractant protein 1) FOXA2 (transcription) EfnB1(projecting axons)
Itgb1 (integrin 1) VIM (cytoskeleton; Furuta et al., 2010) NR3C2 (Mineralocorticoid and gluco-
corticoid receptor)
SCP1 (synaptonemal ﬁlaments) SMYD3 (transcription; Furuta et al., 2010)
hsa-let-7g C-Myc (transcription) Collagen alpha2 (COL1A2) Bcl-xL (cell death)
hsa-miR-196a HOX-B7 (transcription) SPRR2C (small proline-rich protein 2C) Annexin A1 (exocytosis)
S100A9 (calcium-binding protein A9) KRT5 (keratin 5) HOXC8 (transcription)
hsa-miR-542-3p Survivin
hsa-miR-525-5p VPAC1 (vasoactive intestinal peptide receptor 1)
Table 2 | Additional targets of microRNAs targeting AChE-R.
miR ID Validated targets
Hsa-miR-708 MPL (thrombopoietin receptor; Girardot
et al., 2010)
Hsa-miR-28-5p MPL (thrombopoietin receptor; Girardot
et al., 2010)
OTUB1 (immune system transcription;
Girardot et al., 2010)
N4BP1 (NEDD4 binding protein 1;
Girardot et al., 2010)
TEX261 (apoptosis; Girardot et al., 2010) MAPK1 (megakaryocyte differentiation;
Girardot et al., 2010)
hsa-miR-503 ANLN (actin-binding protein anillin) ATF6 (activating transcription factor 6) CHEK1 (cell cycle)
EIF2C1 (argonaute1) KIF23 (mitotic kinesin-like protein 1) WEE1 (mitosis regulator)
CCNE1 (cyclin E1) CDC25A (cell cycle)
CCND1 (cyclin D1) CDC14A (CDC14 cell division cycle 14
homolog A)




DNMT1 (DNA methyltransferase 1) DNMT3B (CpG island methylation) MITF (microphthalmia-associated
transcription factor)





POMC (pro-opiomelanocortin) CAND1 (ubiquitin ligase regulation) PXR (pregnane X receptor)
hsa-miR-152 CaMKIIα (CNS kinase; Liu et al., 2010) DNMT1 (DNA methyltransferase 1)
hsa-miR-125b TNFα (tumor necrosis factor α) ERBB2 (erythroblastic leukemia viral
oncogene homolog 2)
BMPR1B (bone morphogenic receptor
type 1B)
IRF4 (interferon regulatory factor 4) ERBB3 (erythroblastic leukemia viral
oncogene homolog 3)
E2F3 (cell cycle)
Blimp1 (zinc ﬁnger protein) TEF (thyrotroph embryonic factor) Bcl2 modifying factor (apoptosis)
Vdr (vitamin D receptor) MUC1 (adhesion) Bak1 (pro-apoptotic Bcl2 antagonist
killer 1)
CYP24A1 (cytochrome P450 family 24A) p53 (tumor suppressor) SMO (smoothened receptors)
IGF2 (insulin-like growth factor 2) Suv39h1 (histone methyltransferase) Stat3 (Transcription factor, binds to IL-6)
LIN28 (translational enhancer) NMDA receptor subunit NR2A ATM (ataxia telangiectasia mutated)
(Continued)
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Table 2 | Continued
miR ID Validated targets
hsa-miR-125a-5p LIN28 (translational enhancer) T-TrkC (neurotrophic tyrosine kinase
receptor 3)
HuR (cell growth)
p53 (tumor suppressor) KLF13 (transcription factor) AT-rich interactive domain 3B
(transcription)
PDPN 9 (actin organization) Bak1 (pro-apoptotic Bcl2 antagonist
killer 1)
N-ras (oncogene) MEK3 (phosphorylation of MAP kinase)
hsa-miR-214 SrGAP1(neuronal migration) Ezh2 (stem cell identity) N-ras (oncogene)
JNK1 (MAPK8) PTEN (tumor suppressor) MEK3 (phosphorylation)
hsa-miR-199a-5p Hif-1α (Hypoxia-inducible factor 1) IKKβ (NFκB activation) DDR1 (discoidin domain receptor 1)
Sirt1 (apoptosis)
hsa-miR-31 ICAM-1 (leukocyte adhesion protein) Fgf13 (ﬁbroblast growth factor 13) Dkk-1 (canonicalWnt signaling)
DACT-3 (epigenetic regulator ofWnt) E-selectin (inﬂammation) p16Ink4a (cell cycle)
LATS2 (tumor suppression) PPP2R2A (signal transduction) Krt16 (keratin 16)
Krt17 (keratin 17) Dlx3 (development of ventral forebrain) E2F6 (cell cycle)
TIAM1 (T-cell lymphoma invasion and
metastasis 1)
Fzd3 (accumulation of β-catenin) Integrin α (ﬁbronectin)
M-RIP (regulation of actin) MMP16 (blood vessels matrix remodeling) RDX (actin ﬁlaments binding to plasma
membrane)
RhoA (signal transduction) SATB2 (upper-layer neurons initiation) PROX1 (CNS development)
WAVE3 (signal transmission)
hsa-miR-185 Six1 (limb development)
hsa-miR-193b Estrogen receptor α Mcl-1 (myeloid cell
leukemia sequence 1)
ETS-1 (oncogene) uPA (urokinase-type
plasminogen activator)
CCND1 (cyclin D1)
hsa-miR-7 Alpha-synuclein (SNCA) SFRS1 (splicing) ERF (cell proliferation)
LSH (lymphoid-speciﬁc helicase) DAP (cell death-associated protein) MRP1 (human multidrug resistance-
associated protein 1)
Associated cdc42 kinase 1 Yan (cell differentiation) EGFR (epidermal growth factor receptor)
CD98 (sodium transport) Pak1 (p21-activated kinase 1) IGF1R (insulin-like growth factor 1
receptor)
hsa-miR-483-5p Socs-3 (cytokine signaling) BBC3/PUMA (apoptosis)
hsa-miR-663 TGFβ1 (proliferation) JunB (jun B proto-oncogene) JunD (jun D proto-oncogene)
hsa-miR-765 TRK3 (neurotrophic tyrosine kinase)
hsa-miR-146b-3p IRAK1 (IL1 receptor-associated kinase 1) EGFR (epidermal growth factor receptor) MMP16 (degrades extracellular matrix)
Table 3 | Additional targets of BChE-targeting microRNAs.
miR ID Validated target
hsa-miR-203 SOCS-3 (cytokine signaling) Lef1 (lymphoid enhancer-binding factor) p63 (transcription)
ABL1 (cell growth) Barx1 (transcription) CKAP2 (cytoskeleton associated
protein 2)
LASP1 (cytoskeletal activities) BIRC5 (regulator of mitosis) WASF1 (signal transmission)
ASAP1 (membrane trafﬁcking) RUNX2 (runt-related transcription factor 2)
hsa-miR-340 MITF (microphthalmia-associated
transcription factor)
hsa-miR-218 IKK-β (NFκB activation) ROBO1 (roundabout, axon guidance
receptor, homolog 1)
BIRC5 (mitosis)
GJA1 (gap junction protein, α1) ROBO2 (roundabout, axon guidance
receptor homolog 2)
GLCE (glucuronic acid epimerase)
PXN (paxillin, cytoskeletal protein)
(Continued)
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Table 3 | Continued
miR ID Validated target
hsa-miR-221 ERα (estrogen receptor α) ICAM-1(leukocyte adhesion protein) p27 (cell cycle)
p57 (cyclin-dependent kinase inhibitor 1C) DNA damage-inducible transcript 4
(DDIT4)
TIMP3 (TIMP metallopeptidase inhibitor 3)
PTEN (tumor suppressor) PUMA (apoptosis) C-fos (cell proliferation; Ichimura et al.,
2010)
Bmf (apoptosis) Mdm2 (ubiquitination) CDKN1B (cyclin-dependent kinase
inhibitor 1B)
hsa-miR-222 ERα (estrogen receptor α) p27 (cell cycle) PTEN (tumor suppressor)
STAT5A (transcription) p57 (cyclin-dependent kinase inhibitor 1C) TIMP3 (TIMP metallopeptidase inhibitor 3)
Bim (apoptosis) ETS-1 (transcription) PUMA (apoptosis)
PPP2R2A (protein phosphatase 2A
subunit B)
C-fos (cell proliferation; Ichimura et al.,
2010)
ICAM-1(leukocyte adhesion protein)
MMP1 (cleaves collagens) SOD2 (superoxide dismutase 2)
hsa-miR-181a SIRT1 (apoptosis) Ataxia telangiectasia mutated (ATM; cell
cycle)
Hox-A11 (transcription)
p27(cell cycle) PLAG1 (transcription) BCL2 (B-cell CLL/lymphoma 2; apoptosis)
Bim (apoptosis) Tcl1 (cell proliferation) OPN (osteopontin)
hsa-miR-181b AID (RNA-editing) PLAG1 (transcription) BCL2 (B-cell CLL/lymphoma 2; apoptosis)
TIMP3 (TIMP metallopeptidase inhibitor 3) Ataxia telangiectasia mutated (ATM; cell
cycle)
SIRT1 (apoptosis)
ZNF37A (transcriptional regulation) ZNF83 (transcriptional regulation) ZNF182 (transcriptional regulation)
Mcl-1 (myeloid cell leukemia-1; apoptosis)
hsa-miR-181c IL2 (immune response) BCL2 (B-cell CLL/lymphoma 2; apoptosis) NOTCH4 (transcriptional activator)
KRAS (GTPase activity)
hsa-miR-181d BCL2 (B-cell CLL/lymphoma 2; apoptosis)
hsa-miR-494 CaMKIIδ (CNS kinase) ROCK-1 (apoptosis) LIF [leukemia inhibitory factor (cholinergic
differentiation factor)]
PTEN (phosphatase and tensin homolog) TEL-AML1 (hematopoiesis) FGFR2 (ﬁbroblast growth factor
receptor 2)
hsa-miR-129-5p CAMTA1 (calmodulin binding transcription
activator 1)




hsa-miR-30d Galphai2 (G protein, α inhibiting activity
polypeptide 2)
hsa-miR-30c Runx1 (runt-related transcription factor 1) CTGF (connective tissue growth factor)
hsa-miR-30a SOD2 (superoxide dismutase 2) BDNF (brain-derived neurotrophic factor) Beclin 1 (autophagy)
Xlim1/Lhx1 (transcription factor)
hsa-miR-30e Ubc9 (ubiquitin-conjugating enzyme E2I) B-Myb (transcription factor)
hsa-miR-320a (Hsp20 heat-shock protein 20) AQP1 (aquaporin 1) AQP4 (aquaporin 4)
TfR-1; CD71 (development of erythrocytes
and the nervous system)
Mcl-1 (myeloid cell leukemia sequence 1;
apoptosis)
hsa-miR-140-5p Smad3 (transcription) HDAC4 (histone deacetylase 4)
hsa-miR-519c-3p HIF-1α (hypoxia-inducible factor 1α) ABCG2 (exclusion of xenobiotics from the
brain)
hsa-miR-489 PTPN11 (signal transduction)
hsa-miR-584 NXA1 (exocytosis) ROCK-1 (actin assembly)
We focused our survey on those functions of those miRs
for which experimental validation is available. Table 4 presents
these miRs which are shared for AChE-R and AChE-S or AChE-
R and BChE and some of their additional targets, highlighting
the multitude of miR targets with predicted regulatory functions
(e.g., the chromatin modulator zinc ﬁnger proteins ZEB1 and
ZEB2 targeted by miR-200b, miR-200c, and miR-429 that are also
directed to both AChE-R and AChE-S; Gregory et al., 2008). Like-
wise, the AChE-S-targeted miR-132 (Shaked et al., 2009; Soreq
and Wolf, 2011) also targets the GTPase regulator p250GAP
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Table 4 | Additional targets of ChE-targeting miRs (common to more than one ChE).
miR ID Validated target common to ACHE-R andAChE-S
hsa-miR-186 Pro-apoptotic P2×7 purinergic receptor AKAP12 (tumor suppressor)
hsa-miR-199b-5p Dyrk1a (brain development) HES1 (transcriptional repressor) SET (apoptosis)
hsa-miR-429 ZEB1 (transcriptional repression of IL2;
Gregory et al., 2008)




hsa-miR-200b ZEB1 (transcriptional repression of IL2;
Gregory et al., 2008)





Suz12 (chromatin silencing) Ets-1 (transcriptions factor)
OREBP (osmotic response element) Cyclin D1
hsa-miR-200c ZEB1 (transcriptional repression of IL2;
Gregory et al., 2008)
ZEB2 (SIP1; zinc ﬁnger protein; Gregory
et al., 2008)
PLCgamma1(apoptosis)
VEGF (angiogenesis) TUBB3 (neurogenesis and axon guidance) TRPS1 (transcription factor)
KLF13 (transcription factor) MBNL2 (muscleblind-like protein 2) FAP1 (apoptosis)
miR ID Validated targets common to ACHE-R and BChE
hsa-miR-24 SOD1 (superoxide dismutase 1) ALK4 (transducer of activin) Notch1 (Bergmann glia differentiation)
MKK4 (survival signal in T cells) E2F2 (cell cycle) H2AX (histone-formation)
FAF1 (apoptosis) HNF4α (cell proliferation) FURIN (processing ofTGFβ1)
DHFR (dihydrofolate reductase) DND1(miRNA-mediated gene
suppression)
hsa-miR-212 MeCP2 (interaction with histone
deacetylase) PED (apoptosis)
MYC (transcription) Rb1(tumor suppressor)
hsa-miR-132 AChE-S (Shaked et al., 2009) P250GAP (neuron-associated GTPase; Vo
et al., 2005)
Per1 (circadian clock)
SirT1 (apoptosis) MeCP2 (modiﬁcation of eukaryotic
genomes)
p300 (chromatin remodeling)
Jarid1a (histone demethylase) Btg2 (cell cycle) Paip2a (translation regulation)
p120RasGAP (angiogenesis)
hsa-miR-198 Cyclin T1
hsa-miR-194 Rac1 (GTP-binding protein) Per family (circadian) EP300 (transcriptional co-activator)
MDM2 (p53 negative regulator)
involved in neurite extension (Vo et al., 2005; Hansen et al., 2010;
Table 4).
The process-regulation hypothesis of miR function predicts the
existence of biological functions in which both cholinesterases,
and those other targets which share miRs with cholinesterases,
would be involved. To challenge this hypothesis, we ﬁrst identi-
ﬁed the GO categories in which AChE and BChE are involved,
and found 24 and 11 biological processes for these two pro-
teins, respectively. Twenty-three, 13, and 18 enriched biological
processes emerged as shared processes for the other validated tar-
gets of AChE-R, AChE-S, and BChE-targeting miRs, respectively
(P-value threshold< 0.05).
Out of over 20 ontology categories attributed to AChE, only
two are shared with the categories attributed to the other val-
idated targets of the cholinesterase-targeting miRs. These are:
Response to wounding (GO: 0009611; 68 transcripts) and Neuron
development (GO: 0048666), and speciﬁcally its AChE-relevant
child terms Regulation of axonogenesis (GO: 0050770; 78 tran-
scripts) and regulation of dendrite morphogenesis (GO: 0048814;
27 transcripts). Surprisingly, all 10 miRs that regulate Response
to wounding and Neuron development selectively target the nor-
mally rare, stress-responsive AChE-R transcript, (miR-186, -125b,
-200c, -199a-5p, -199b-5p, -125a, -214, -7, -663, -31, and -
148a) whereas only three of these miRs also target the preva-
lent AChE-S mRNA (miR-194, -24, and -132). For BChE, we
found only one shared category out of 11 relevant ontology
groups: Response to glucocorticoid stimulus (GO: 0051384; 119
transcripts), and no overlap with the AChE-relevant categories
(Figures 3A,B).
DISCUSSION
Using a variety of available algorithms, we found a plethora of
cholinesterase-targeted miRs. Some of these were already vali-
dated as functionally capable of silencing othermRNA transcripts.
A study of the functionally relevant biological processes in which
these other targets are involved revealed a highly focused overlap
with only few of the biological processes in which cholinesterases
participate. Given thatmiRs regulate targetswhich share biological
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FIGURE 3 | MiR regulators of biological processes shared by
cholinesterases and validated targets of these miRs. (A) miRs targeting
transcripts participating in the AChE-S and AChE-R relevant response to
wounding (yellow)and neuron development processes(blue) or both
categories(green). (B) miRs targeting transcripts participating in the
BChE-relevant response to glucocorticoid stimulus category.
processes, cholinesterases appear to be primarily subject to miR
regulation when involved in neuronal development, response to
wounding, and glucocorticoid stimulus; and speciﬁc cholinergic
processes are regulated by miRs targeting both AChE and other
targets participating in the same biological process.
Several limitations should be considered in the context of this
study. First, the currently available search algorithms for miR
candidates appear to differ substantially, which casts a shadow
on the veracity of such identiﬁcation. Second, research bias
has focused much of the efforts in the miR ﬁeld toward can-
cer research, whereas neuroscience-focused miRs were relatively
neglected. Therefore, we might have overlooked important miRs
simply because they have not yet been validated experimentally.
This being said, that many of the biological functions in which
cholinesterases are involved show no relevant cholinesterase-
targeting miR sequences suggests other modes of regulation of
cholinesterase levels for most of these functions [e.g., transcrip-
tional (Hill and Treisman, 1995), epigenetic (Allshire and Karpen,
2008), or post-translational processes (Fukushima et al., 2009)].
Alternatively, or in addition, miRs might exist which control
these functions, but have no role in cancer biology and are
therefore not yet characterized. MiR regulation of cholinesterase
functions will therefore need to be re-inspected in the near
future.
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APPENDIX
Table A1 | Additional targets of AChE-S targeting microRNAs.
miR ID Validated targets
hsa-miR-491-5p Bcl-X (L; cell death; Nakano et al., 2010)
hsa-miR-605 Mdm2 (ubiquitination; Xiao et al., 2011)
hsa-miR-608 CD44 (cell–cell/cell–matrix interaction;
Jeyapalan et al., 2011)
CDC42 (cell division; Jeyapalan et al.,
2011)
hsa-miR-124 Glucocorticoid receptor (Vreugdenhil et al.,
2009)
LAMC1 (laminin γ1; Cao et al., 2007) IQGAP1(neurite outgrowth; Furuta
et al., 2010)
NeuroD1 (neurogenic differentiation 1; Liu et al.,
2011)
BAF53a (chromatin remodeling; Yoo et al.,
2009)
C14orf24 (chromosome 14 open
reading frame 24; Ko et al., 2009)
Mtpn (myotrophin; Krek et al., 2005) PTBP1 (splicing; Makeyev et al., 2007) CDK6 (cyclin-dependent kinase 6;
Pierson et al., 2008)
Mapk14 (mitogen activated protein kinase 14;
Krek et al., 2005)
PTBP2 (splicing; Makeyev et al., 2007) SOX9 (glial cell speciﬁcation; Cheng
et al., 2009)
CDK2 (cyclin-dependent kinase 2; Nakamachi
et al., 2009)
C/EBPα (transcription factor; Hackanson
et al., 2008)
Lhx2 (transcription; Qiu et al., 2009)
MCP- (1 monocyte chemoattractant protein 1;
Nakamachi et al., 2009)




Itgb1 (integrin 1; Cao et al., 2007) VIM (cytoskeleton; Furuta et al., 2010) NR3C2 (mineralocorticoid and glu-
cocorticoid receptor; Sober et al.,
2010)
SCP1 (synaptonemal ﬁlaments; Cao et al., 2007) SMYD3 (transcription; Furuta et al., 2010)
hsa-let-7g C-Myc (transcription factor; Lan et al., 2011) Collagen alpha2 (COL1A2; Ji et al., 2010) Bcl-xL (cell death; Shimizu et al.,
2010)
hsa-miR-196a HOX-B7 (transcription factor; Braig et al., 2010) SPRR2C (small proline-rich protein 2C;
Maru et al., 2009)
Annexin A1 (exocytosis; Luthra
et al., 2008)
S100A9 (calcium-binding protein A9; Maru et al.,
2009)
KRT5 (keratin 5; Maru et al., 2009) HOXC8 (transcription factor; Kim
et al., 2009a)
hsa-miR-542-3p Survivin (Yoon et al., 2010)
hsa-miR-525-5p VPAC1 (vasoactive intestinal peptide receptor 1;
Cocco et al., 2010)
miRswithout validated targets: hsa-miR-920, -506, -27b ∗, -541, -92a-2 ∗, -658, -423-5p, -615-5p, -25 ∗, -4688, -4776-3p, -668, -3613-5p, -4700-5p, -718, let-7f-2 ∗, -455-3p,
-633, -554, -524-3p, -638, -525-3p, -611, let-7e ∗, -4283, -4329, -4278, -4300, -3184, -149 ∗.
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Table A2 | Additional targets of microRNAs targeting AChE-R.
miR ID Validated targets
hsa-miR-708 MPL (thrombopoietin receptor; Girardot
et al., 2010)
hsa-miR-28-5p MPL (thrombopoietin receptor; Girardot
et al., 2010)
OTUB1 (immune system transcription;
Girardot et al., 2010)
N4BP1 (NEDD4 binding protein 1;
Girardot et al., 2010)
TEX261 (apoptosis; Girardot et al., 2010) MAPK1 (megakaryocyte differentiation;
Girardot et al., 2010)
hsa-miR-503 ANLN (actin-binding protein anillin; Forrest
et al., 2010)
ATF6 (activating transcription factor 6;
Forrest et al., 2010)
CHEK1 (checkpoint mediated cell cycle
arrest; Forrest et al., 2010)
EIF2C1 (argonaute1; Forrest et al., 2010) KIF23 (mitotic kinesin-like protein 1;
Forrest et al., 2010)
WEE1 (mitosis regulator; Forrest et al.,
2010)
CCNE1 (cyclin E1; Forrest et al., 2010) CDC25A (cell cycle progression; Forrest
et al., 2010)
CCND1 (cyclin D1; Forrest et al., 2010) CDC14A (CDC14 cell division cycle 14
homolog A; Forrest et al., 2010)
hsa-miR-148a CaMKIIα (CNS kinase; Liu et al., 2010e) MLC1 (megalencephalic
leukoencephalopathy with subcortical
cysts 1; Geisler et al., 2011)
MSK1 (histone phosphorylase; Fujita
et al., 2010)
DNMT1 (DNA methyltransferase 1; Pan
et al., 2010)
DNMT3B (CpG island methylation;
Duursma et al., 2008)
MITF (microphthalmia-associated tran-
scription factor; Haﬂidadottir et al.,
2010)
CCKBR (modulates anxiety, analgesia,
arousal, and neuroleptic activity;
Muinos-Gimeno et al., 2011)
EPAS1 (endothelial PAS
domain-containing protein 1;
Giraud-Triboult et al., 2011)
HLA-G (asthma susceptibility; Tan et al.,
2007)
POMC (pro-opiomelanocortin;
Muinos-Gimeno et al., 2011)
CAND1 (ubiquitin ligase regulation;
Murata et al., 2010)
PXR (pregnane X receptor; Takagi et al.,
2008)
hsa-miR-152 CaMKIIα (CNS kinase; Liu et al., 2010e) DNMT1 (DNA methyltransferase 1;
Braconi et al., 2010a)
hsa-miR-125b TNFα (tumor necrosis factor α; Tili et al.,
2007)
ERBB2 (erythroblastic leukemia viral
oncogene homolog 2; Scott et al., 2007)
BMPR1B (bone morphogenic receptor
type 1B; Saetrom et al., 2009)
IRF4 (interferon regulatory factor 4;
Malumbres et al., 2009)
ERBB3 erythroblastic leukemia viral
oncogene homolog 3; Scott et al., 2007)
E2F3 (cell cycle control; Huang et al.,
2011a)
Blimp1 (zinc ﬁnger protein; Zhang et al.,
2011b)
TEF (thyrotroph embryonic factor;
Gutierrez et al., 2011)
Bcl2 modifying factor (apoptosis; Xia
et al., 2009b)
Vdr (vitamin D receptor; Zhang et al.,
2011b)
MUC1 (adhesion; Rajabi et al., 2010) Bak1 (pro-apoptotic Bcl2 antagonist killer
1; Zhou et al., 2010)
CYP24A1 (cytochrome P450, family 24A,
polypeptide 1; Komagata et al., 2009)
p53 (tumor suppressor; Le et al., 2009) SMO (smoothened receptors; Ferretti
et al., 2008)
IGF2 (insulin-like growth factor 2; Ge
et al., 2011)
Suv39h1 (histone methyltransferase;
Villeneuve et al., 2010)
Stat3 (transcription factor binds to IL-6;
Surdziel et al., 2011)
LIN28 (translational enhancer; Zhong
et al., 2010)
NMDA receptor subunit NR2A (Edbauer
et al., 2010)
ATM (ataxia telangiectasia mutated;
Smirnov and Cheung, 2008)
hsa-miR-125a-5p LIN28 (translational enhancer;Wu and
Belasco, 2005)
T-TrkC (neurotrophic tyrosine kinase
receptor 3; Ferretti et al., 2009)
HuR (cell growth; Guo et al., 2009)
p53 (tumor suppressor; Zhang et al., 2009) KLF13 (transcription factor; Zhao et al.,
2010)
AT-rich interactive domain 3B (tran-
scription factor; Cowden Dahl et al.,
2009)
PDPN 9 (actin organization; Cortez et al.,
2010)
Bak1 (pro-apoptotic Bcl2 antagonist killer
1; Guo et al., 2010)
N-ras (oncogene; Juan et al., 2009) MEK3 (phosphorylation of MAP kinase; Li
et al., 2011)
(Continued)
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Table A2 | Continued
miR ID Validated targets
hsa-miR-214 SrGAP1(neuronal migration; Zhang et al.,
2011a)
Ezh2 (stem cell identity; Juan et al., 2009) N-ras (oncogene; Liu et al., 2010b)
JNK1 (MAPK8; Yang et al., 2009) PTEN (tumor suppressor; Yang et al.,
2009)
MEK3 (phosphorylation;Yang et al., 2009)
hsa-miR-199a-5p Hif-1α (hypoxia-inducible factor 1; Rane
et al., 2009)
Sirt1 (apoptosis; Rane et al., 2009) DDR1 (discoidin domain receptor 1; Shen
et al., 2010)
IKKβ (NFκB activation; Chen et al., 2008)
hsa-miR-31 ICAM-1 (leukocyte adhesion protein;
Suarez et al., 2010)
Fgf13 (ﬁbroblast growth factor 13;
Mardaryev et al., 2010)
Dkk-1 (canonicalWnt signaling; Xi et al.,
2010)
DACT-3 (epigenetic regulator ofWnt; Xi
et al., 2010)
E-selectin (inﬂammation; Suarez et al.,
2010)
p16Ink4a (cell cycle; Malhas et al., 2010)
LATS2 (tumor suppression; Liu et al.,
2010c)
PPP2R2A (signal transduction; Liu et al.,
2010c)
Krt16 (keratin 16; Mardaryev et al., 2010)
Krt17 (keratin 17; Mardaryev et al., 2010) Dlx3 (development of ventral forebrain;
Mardaryev et al., 2010)
E2F6 (cell cycle; Bhatnagar et al., 2010)
TIAM1 (T-cell lymphoma invasion and
metastasis 1; Cottonham et al., 2010)
Fzd3 (accumulation of β-catenin; Valastyan
et al., 2009)
Integrin α (ﬁbronectin; Valastyan et al.,
2009)
M-RIP (regulation of actin; Valastyan et al.,
2009)
MMP16 (blood vessels matrix
remodeling; Valastyan et al., 2009)
RDX (actin ﬁlaments binding to plasma
membrane; Valastyan et al., 2009)
RhoA (signal transduction; Valastyan et al.,
2009)
SATB2 (upper-layer neurons initiation;
Aprelikova et al., 2010)
PROX1 (CNS development; Pedrioli et al.,
2010)
WAVE3 (signal transmission;
Sossey-Alaoui et al., 2010)
hsa-miR-185 Six1 (limb development; Imam et al., 2010)
hsa-miR-193b Estrogen receptor α (Leivonen et al.,
2009)
ETS-1 (oncogene; Xu et al., 2010a) CCND1 (cyclin D1; Xu et al., 2010a)
Mcl-1 (myeloid cell leukemia sequence 1;
Braconi et al., 2010b)
uPA (urokinase-type plasminogen
activator; Li et al., 2009b)
hsa-miR-7 Alpha-synuclein (SNCA; Junn et al., 2009) SFRS1 (Wu et al., 2010b) ERF (cell proliferation; Chou et al., 2010)
LSH (lymphoid-speciﬁc helicase; Ilnytskyy
et al., 2008)
DAP (cell death-associated protein; Yu
et al., 2009)
MRP1 (human multidrug resistance-
associated protein 1; Pogribny et al.,
2010)
Associated cdc42 kinase 1 (Saydam et al.,
2011)
Yan (cell differentiation; Li and Carthew,
2005)
EGFR (epidermal growth factor receptor;
Kefas et al., 2008)
CD98 (sodium transport; Nguyen et al.,
2010)
Pak1 (p21-activated kinase 1; Reddy et al.,
2008)
IGF1R (insulin-like growth factor 1
receptor; Jiang et al., 2010)
hsa-miR-483-5p Socs-3 (cytokine signaling; Ma et al., 2011) BBC3/PUMA (apoptosis; Veronese et al.,
2010)
hsa-miR-663 TGFβ1 (proliferation; Tili et al., 2010b) JunB (jun B proto-oncogene; Tili et al.,
2010a)
JunD (jun D proto-oncogene; Tili et al.,
2010a)
hsa-miR- 765 TRK3 (neurotrophic tyrosine kinase; Guidi
et al., 2010)
hsa-miR- 146b-3p IRAK1 (interleukin-1 receptor-associated
kinase 1; Taganov et al., 2006)
EGFR (epidermal growth factor receptor;
Shao et al., 2011)
MMP16 (degrades extracellular matrix;
Xia et al., 2009a)
miRs without validated targets that are predicted to target AChE-R: hsa-miR-590-3p, -148b, -193a-3p, -182∗, -4298, -4644, -4739, -1224-3p, -4769-5p, –582-3p, -380∗,
-1825, -892b, -1275, -3155, -765, -3119, -3139, -563, -92b∗, -1321, -4283, -1228∗, -4323, -4319, -761, -767-5p, -224∗, -522, -4271, -1226∗, -3179, -92a-1∗, -3202, -20b∗,
-4303, -4306, -3065-5p, -4297, -4329, -3148, -3163, -22∗, -4302, -513a-5p, -542-5p, -377∗, -1908, -92a-2∗, -608, -625.
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Table A3 | Additional targets of BChE-targeting microRNAs.
miR ID Validated target
hsa-miR-203 SOCS-3 (cytokine signaling;Wei et al.,
2010)
Lef1 (lymphoid enhancer-binding factor;
Thatcher et al., 2008)
p63 (transcriptional activator or repressor;
Yi et al., 2008)
ABL1 (cell growth; Bueno et al., 2008) Barx1 (transcription factor; Kim et al.,
2011)
CKAP2 (cytoskeleton associated protein
2; Viticchie et al., 2011)
LASP1 (cytoskeletal activities; Viticchie
et al., 2011)
BIRC5 (regulator of mitosis; Viticchie
et al., 2011)
WASF1 (signal transmission; Viticchie
et al., 2011)
ASAP1 (membrane trafﬁcking; Viticchie
et al., 2011)
RUNX2 (runt-related transcription factor 2;
Viticchie et al., 2011)
hsa-miR-340 MITF (microphthalmia-associated
transcription factor; Goswami et al., 2010)
hsa-miR-218 IKK-β (cytokine-activated intracellular
signaling pathway; Song et al., 2010)
ROBO1 (roundabout, axon guidance
receptor, homolog 1; Alajez et al., 2011)
BIRC5 (regulator of mitosis; Alajez et al.,
2011)
GJA1 (gap junction protein, α1; Alajez
et al., 2011)
ROBO2 (roundabout, axon guidance
receptor homolog 2; Alajez et al., 2011)
GLCE (glucuronic acid epimerase; Small
et al., 2010)
PXN (paxillin, cytoskeletal protein;Wu
et al., 2010a)
hsa-miR-221 ERα (estrogen receptor α; Zhao et al.,
2008)
ICAM-1 (leukocyte adhesion protein; Hu
et al., 2010)
p27 (cell cycle; Garofalo et al., 2008)
p57 (cyclin-dependent kinase inhibitor 1C;
Kim et al., 2009b)
DNA damage-inducible transcript 4
(DDIT4; Pineau et al., 2010)
TIMP3 (TIMP metallopeptidase inhibitor 3;
Garofalo et al., 2009)
PTEN (tumor suppressor; Garofalo et al.,
2009)
PUMA (apoptosis; Zhang et al., 2010) C-fos (cell proliferation; Ichimura et al.,
2010)
Bmf (apoptosis; Gramantieri et al., 2009) Mdm2 (ubiquitination; Kim et al., 2010) CDKN1B (cyclin-dependent kinase
inhibitor 1B; Kotani et al., 2009)
hsa-miR-222 ERα (estrogen receptor α; Zhao et al.,
2008)
p27 (cell cycle; Garofalo et al., 2008) PTEN (tumor suppressor; Garofalo et al.,
2009)
STAT5A (signal transducer and activator of
transcription 5; Dentelli et al., 2010)
p57 (cyclin-dependent kinase inhibitor 1C;
Kim et al., 2009b)
TIMP3 (TIMP metallopeptidase inhibitor 3;
Garofalo et al., 2009)
Bim (apoptosis; Terasawa et al., 2009) ETS-1 (transcription factor; Zhu et al.,
2011)
PUMA (apoptosis; Zhang et al., 2010)
PPP2R2A (protein phosphatase 2A
subunit B;Wong et al., 2010)
C-fos (cell proliferation; Ichimura et al.,
2010)
ICAM-1 (Ueda et al., 2009)
MMP1 (cleaves collagens; Liu et al., 2009) SOD2 (superoxide dismutase 2; Liu et al.,
2009)
hsa-miR-181a SIRT1 (apoptosis, muscle differentiation;
Saunders et al., 2010)
Ataxia telangiectasia mutated (ATM; cell
cycle;Wang et al., 2011)
Hox-A11 (transcription factor; Naguibneva
et al., 2006)
p27(cell cycle; Cuesta et al., 2009) PLAG1 (transcription factor; Pallasch et al.,
2009)
BCL2 (B-cell CLL/lymphoma 2; apoptosis;
Zhu et al., 2010)
Bim (apoptosis; Lwin et al., 2010) Tcl1 (cell proliferation; Pekarsky et al.,
2006)
OPN (osteopontin; Bhattacharya et al.,
2010)
hsa-miR-181b AID (activation-induced cytidine
deaminase; RNA-editing; DeYebenes
et al., 2008)
PLAG1 (transcription factor; Pallasch et al.,
2009)
BCL2 (B-cell CLL/lymphoma 2; apoptosis;
Zhu et al., 2010)
TIMP3 (TIMP metallopeptidase inhibitor 3;
Wang et al., 2010a)
Ataxia telangiectasia mutated (ATM; cell
cycle;Wang et al., 2011)
SIRT1 (apoptosis, muscle differentiation;
Saunders et al., 2010)
ZNF37A (transcriptional regulation; Huang
et al., 2010)
ZNF83 (transcriptional regulation; Huang
et al., 2010)
ZNF182 (transcriptional regulation; Huang
et al., 2010)
Mcl-1 (myeloid cell leukemia-1; apoptosis;
Zimmerman et al., 2010)
hsa-miR-181c IL2 (immune response; Xue et al., 2011) BCL2 (B-cell CLL/lymphoma 2; apoptosis;
Zhu et al., 2010)
NOTCH4 (transcriptional activator
complex; Hashimoto et al., 2010)
(Continued)
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Table A3 | Continued
miR ID Validated target
KRAS (GTPase activity; Hashimoto et al.,
2010)
hsa-miR-181d BCL2 (B-cell CLL/lymphoma 2; Zhu et al.,
2010)
hsa-miR-494 CaMKIIδ (CNS kinase;Wang et al., 2010b) ROCK-1 (apoptosis; Wang et al., 2010b) LIF (leukemia inhibitory factor (cholinergic
differentiation factor);Wang et al., 2010b)
PTEN (phosphatase and tensin homolog;
Wang et al., 2010b)
TEL-AML1 (hematopoiesis; Diakos et al.,
2010)
FGFR2 (ﬁbroblast growth factor receptor
2;Wang et al., 2010b)
hsa-miR-129-5p CAMTA1 (calmodulin binding transcription
activator 1; Liao et al., 2008)
EIF2C3 (eukaryotic translation initiation
factor 2C, 3; Liao et al., 2008)
GALNT1 (oligosaccharide biosynthesis;
Dyrskjot et al., 2009)
SOX4 (transcriptional activator; Dyrskjot
et al., 2009)
hsa-miR-30d Galphai2 (G protein, α inhibiting activity
polypeptide 2; Yao et al., 2010)
hsa-miR-30c Runx1 (runt-related transcription factor 1;
Ben-Ami et al., 2009)
CTGF (connective tissue growth factor;
Duisters et al., 2009)
hsa-miR-30a SOD2 (superoxide dismutase 2; Xia et al.,
2006)
BDNF (brain-derived neurotrophic factor;
Mellios et al., 2008)
Beclin 1 (autophagy; Zhu et al., 2009)
Xlim1/Lhx1 (transcription factor; Agrawal
et al., 2009)
hsa-miR-30e Ubc9 (ubiquitin-conjugating enzyme E2I;
Wu et al., 2009)
B-Myb (transcription factor; Martinez
et al., 2011)
hsa-miR-320a (Hsp20 heat-shock protein 20; Ren et al.,
2009)
AQP1 (aquaporin 1; Sepramaniam et al.,
2010)
AQP4 (aquaporin 4; Sepramaniam et al.,
2010)
The transferrin receptor 1(TfR-1; CD71;
development of erythrocytes and the
nervous system; Schaar et al., 2009)
Mcl-1 (myeloid cell leukemia sequence 1;
apoptosis; Chen et al., 2009)
hsa-miR-140-5p Smad3 (transcriptional modulator; Pais
et al., 2010)
HDAC4 (histone deacetylase 4;
Tuddenham et al., 2006)
hsa-miR-519c-3p HIF-1α (hypoxia-inducible factor 1α; Cha
et al., 2010)
ABCG2 (exclusion of xenobiotics from the
brain; To et al., 2008)
hsa-miR-489 PTPN11 (signal transduction; Kikkawa
et al., 2010)
hsa-miR-584 NXA1 (exocytosis; Luthra et al., 2008) ROCK-1 (actin assembly; Ueno et al.,
2011)
miRs without validated targets: hsa-miR-147b, -532-5p, -508-3p, -889, -325, -573, -195∗, -567, -193b∗, -625, -16-2∗, -576-3p, -190b, -518e∗, -518f∗, -518d-5p, -147, -320d,
-320c, -320b, -875-5p, -758, -30b, -1279, -3145, -1183, -664, -4261, -4262, -1237, -1972, -3146, let-7a-2∗, let-7g∗, -1911∗, -2052, -15a∗, -3148, -555, -656, -636, -3182,
-513a-3p, -501-3p, -502-3p, -579, -4316, -4312, -1294, -142-5p, -3128, -30a∗, -30d∗, -30e∗, -4268, -3137, -20b∗, -651, -32∗, -362-5p, -500b, -501-5p, -1976, -449c∗, -1224-5p,
-302a∗, -1248, -99b∗, -99a∗, -369-3p, -1256, -629, -187∗, -514b-3p, -378∗, -1305, -331-5p, -1200, -4272, -4260, -493∗, -582-5p, -4255, -3133, -4273, -19a∗, -19b-1∗, -19b-2∗,
-4271, -15b∗, -1826.
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Table A4 | Additional targets of ChE-targeting miRs (common to more than one ChE).
miR ID Validated target common to ACHE-R andAChE-S
Hsa-miR-186 Pro-apoptotic P2×7 purinergic
receptor(Zhou et al., 2008)
AKAP12 (tumor suppressor; Goeppert
et al., 2010)
Hsa-miR-199b-5p Dyrk1a (brain development; Da Costa
Martins et al., 2010)
HES1 (transcriptional repressor; Garzia
et al., 2009)
SET (apoptosis; Chao et al., 2010)
Hsa-miR-429 ZEB1 (transcriptional repression of IL2;
Gregory et al., 2008)




RERE (apoptosis; Karres et al., 2007)
Hsa-miR-200b ZEB1 (transcriptional repression of IL2;
Gregory et al., 2008)





Ca2+-ATPase; Salomonis et al., 2010)
Suz12 (chromatin silencing; Iliopoulos
et al., 2010)
Ets-1 (transcriptions factor; Chan et al.,
2011)
OREBP (osmotic response element; Huang
et al., 2011b)
Cyclin D1 (Xia et al., 2010)
Hsa-miR-200c ZEB1 (transcriptional repression of IL2;
Gregory et al., 2008)




VEGF (angiogenesis; Liu et al., 2010a) TUBB3 (neurogenesis and axon guidance;
Cochrane et al., 2009)
TRPS1 (transcription factor; Li et al.,
2009a)
KLF13 (transcription factor; Li et al., 2009a) MBNL2 (muscleblind-like protein 2; Li
et al., 2009a)
FAP1 (apoptosis; Schickel et al., 2010)
miR ID Validated targets common to ACHE-R and BChE
Hsa-miR-24 SOD1 (superoxide dismutase 1; Papaioannou
et al., 2011)
ALK4 (transducer of activin;Wang et al.,
2008)
Notch1 (Bergmann glia differentiation;
Fukuda et al., 2005)
MKK4 (survival signal in T cells; Marasa et al.,
2009)
E2F2 (cell cycle; Lal et al., 2009a) H2AX (histone-formation; Lal et al.,
2009b)
FAF1 (apoptosis; Qin et al., 2010) HNF4α (cell proliferation; Takagi et al.,
2010)
FURIN (processing ofTGFβ1; Luna
et al., 2011)
DHFR (dihydrofolate reductase; Mishra et al.,
2009)
DND1(miRNA-mediated gene
suppression; Liu et al., 2010d)
Hsa-miR-212 MeCP2 (interaction with histone
deacetylase; Im et al., 2010)
MYC (transcription; Xu et al., 2010b) Rb1(tumor suppressor; Park et al.,
2011)
PED (apoptosis; Incoronato et al., 2010)
Hsa-miR-132 AChE-S (Shaked et al., 2009) P250GAP (neuron-associated GTPase; Vo
et al., 2005)
Per1 (circadian clock; Cheng et al.,
2007)
SirT1 (apoptosis; Strum et al., 2009) MeCP2 (modiﬁcation of eukaryotic
genomes; Klein et al., 2007)
p300 (chromatin remodeling; Lagos
et al., 2010)
Jarid1a (histone demethylase;
Alvarez-Saavedra et al., 2011)
Btg2 (cell cycle; Alvarez-Saavedra et al.,
2011)
Paip2a (translation regulation;
Alvarez-Saavedra et al., 2011)
p120RasGAP (angiogenesis; Anand et al.,
2010)
Hsa-miR-198 Cyclin T1(Xu et al., 2010b)
Hsa-miR-194 Rac1 (GTP-binding protein; Venugopal et al.,
2010)
Per family (circadian; Nagel et al., 2009) EP300 (transcriptional co-activator;
Mees et al., 2010)
MDM2 (p53 negative regulator; Pichiorri
et al., 2010)
miRs without validated targets: hsa-miR-423-3p, -484, -4728-3p, -939, -484, -4728-3p.
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